scholarly journals In vitro Activity of Allicin Alone and in Combination With Antifungal Drugs Against Microsporum canis Isolated From Patients With Tinea Capitis

2021 ◽  
Vol 8 ◽  
Author(s):  
Ya Bin Zhou ◽  
Yuan Yuan Xiao ◽  
Jin Jing Chao ◽  
Lin Ma
Keyword(s):  
Tinea Capitis ◽  
Geometric Mean ◽  
Antifungal Drugs ◽  
Vitro Activity ◽  
Microsporum Canis ◽  
In Vitro Activity

The checkerboard broth method based on the Clinical and Laboratory Standards Institute M38-A3 document was used in this study to evaluate the in vitro activity of allicin alone and in combination with the antifungal drugs (griseofulvin, fluconazole, itraconazole and terbinafine) against Microsporum canis isolated from patients with tinea capitis. When allicin was used alone, only weak anti-M. canis effects were found. The MIC50, MIC90 and geometric mean (GM) of terbinafine were the lowest among the compounds tested. Synergism was observed for the combinations of allicin with itraconazole and terbinafine. Only indifference was observed for the combinations of allicin with griseofulvin and fluconazole. Our study illustrated the synergism of allicin in combination with itraconazole and terbinafine, which could be a reference for the treatment of tinea capitis due to M. canis.

scholarly journals 688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S312-S313 ◽  
Author(s):  
Eugenie Basseres ◽  
Julie Miranda ◽  
Anne J Gonzales-Luna ◽  
Travis J Carlson ◽  
Tasnuva Rashid ◽  
...  
Keyword(s):  
Geometric Mean ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Large Collection ◽  
In Vitro Susceptibility ◽  
Clostridioides Difficile ◽  
Clostridioides Difficile Infection ◽  
Abdominal Infections ◽  
Insight Into

Abstract Background Eravacycline is a novel, tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in adults. In clinical trials, patients given eravacycline had a low likelihood of developing Clostridioides difficile infection (CDI). We hypothesized this was likely due, in part, to the in vitro susceptibility of eravacycline to C. difficile. The purpose of this study was to test the in vitro susceptibility of eravacycline vs. comparators on contemporary clinical isolates representing common ribotypes, including isolates with decreased susceptibility to metronidazole and vancomycin. Methods Two hundred and thirty-four isolates from our biobank were selected from the six most common ribotypes (F001, F002, F014-020, F027, F106, and F255). Minimum inhibitory concentrations (MIC) at 24 hours were measured according to CLSI guidelines for eravacycline, vancomycin, metronidazole and fidaxomicin. MICs results were tabulated and are presented as the geometric mean by ribotype. Results Geometric MIC results are shown in Table 1. Eravacycline was the most potent antimicrobial tested followed by fidaxomicin, metronidazole, and vancomycin. Results were consistent amongst all ribotypes, including isolates with reduced susceptibility to vancomycin and metronidazole. Conclusion Eravacycline displayed potent in vitro activity against a large collection of clinical C. difficile isolates. These data provide insight into why patients given eravacycline had a low likelihood of developing CDI and support further research to better understand the use of eravacycline to prevent or potentially treat patients with CDI. Disclosures All authors: No reported disclosures.

scholarly journals Comparison of In Vitro Activity of Liposomal Nystatin againstAspergillus Species with Those of Nystatin, Amphotericin B (AB) Deoxycholate, AB Colloidal Dispersion, Liposomal AB, AB Lipid Complex, and Itraconazole

1999 ◽  
Vol 43 (5) ◽  
pp. 1264-1266 ◽  
Author(s):  
Karen L. Oakley ◽  
Caroline B. Moore ◽  
David W. Denning
Keyword(s):  
Amphotericin B ◽  
Aspergillus Terreus ◽  
Antifungal Agents ◽  
Geometric Mean ◽  
Colloidal Dispersion ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Lipid Complex

ABSTRACT We compared the in vitro activity of liposomal nystatin (Nyotran) with those of other antifungal agents against 60Aspergillus isolates. Twelve isolates were itraconazole resistant. For all isolates, geometric mean (GM) MICs (micrograms per milliliter) were 2.30 for liposomal nystatin, 0.58 for itraconazole, 0.86 for amphotericin B (AB) deoxycholate, 9.51 for nystatin, 2.07 for liposomal AB, 2.57 for AB lipid complex, and 0.86 for AB colloidal dispersion. Aspergillus terreus (GM, 8.72 μg/ml; range, 8 to 16 μg/ml) was significantly less susceptible to all of the polyene drugs than all other species (P = 0.0001).

scholarly journals In Vitro Activities of Terbinafine againstAspergillus Species in Comparison with Those of Itraconazole and Amphotericin B

2001 ◽  
Vol 45 (6) ◽  
pp. 1882-1885 ◽  
Author(s):  
Caroline B. Moore ◽  
Caroline M. Walls ◽  
David W. Denning
Keyword(s):  
Aspergillus Fumigatus ◽  
Amphotericin B ◽  
Geometric Mean ◽  
Vitro Activity ◽  
Clinical Correlation ◽  
In Vitro Activity

ABSTRACT Compared with the in vitro activities of itraconazole (geometric mean MIC [GM], 0.56 μg/ml) and amphotericin B (GM, 0.66 μg/ml), the in vitro activity of terbinafine was inferior againstAspergillus fumigatus (GM, 19.03 μg/ml) (P < 0.05) and superior against A. flavus(GM, 0.10 μg/ml), A. terreus (GM, 0.16 μg/ml), andA. niger (GM, 0.19 μg/ml). Clinical correlation is required, as trailing endpoints are problematic.

scholarly journals In vitro activity of conventional antifungal drugs and natural essences against the yeast-like alga Prototheca

2008 ◽  
Vol 61 (6) ◽  
pp. 1312-1314 ◽  
Author(s):  
A. M. Tortorano ◽  
A. Prigitano ◽  
G. Dho ◽  
R. Piccinini ◽  
V. Dapra ◽  
...  
Keyword(s):  
Antifungal Drugs ◽  
Vitro Activity ◽  
In Vitro Activity

scholarly journals Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms

Mycoses ◽  
2011 ◽  
Vol 55 (1) ◽  
pp. 80-85 ◽  
Author(s):  
Margarida Martins ◽  
Mariana Henriques ◽  
José L. Lopez-Ribot ◽  
Rosário Oliveira
Keyword(s):  
Candida Albicans ◽  
Antifungal Drugs ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Candida Albicans Biofilms

scholarly journals Multicentre Etest evaluation of in vitro activity of conventional antifungal drugs against European bovine mastitis Prototheca spp. isolates

2012 ◽  
Vol 67 (8) ◽  
pp. 1945-1947 ◽  
Author(s):  
T. Jagielski ◽  
P. Buzzini ◽  
H. Lassa ◽  
E. Malinowski ◽  
E. Branda ◽  
...  
Keyword(s):  
Bovine Mastitis ◽  
Antifungal Drugs ◽  
Vitro Activity ◽  
In Vitro Activity

scholarly journals In Vitro Activity of Carbosilane Cationic Dendritic Molecules on Prevention and Treatment of Candida Albicans Biofilms

Pharmaceutics ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 918
Author(s):  
Irene Heredero-Bermejo ◽  
Natalia Gómez-Casanova ◽  
Sara Quintana ◽  
Juan Soliveri ◽  
Francisco Javier de la Mata ◽  
...  
Keyword(s):  
Cell Viability ◽  
Biofilm Formation ◽  
Fungal Pathogens ◽  
Resistance Mechanisms ◽  
Antifungal Drugs ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Candida Spp ◽  
Screening Process

Candida spp. are one of the most common fungal pathogens. Biofilms formed by Candidaalbicans offer resistance mechanisms against most antifungal agents. Therefore, development of new molecules effective against these microorganisms, alone or in combination with antifungal drugs, is extremely necessary. In the present work, we carried out a screening process of different cationic carbosilane dendritic molecules against C. albicans. In vitro activity against biofilm formation and biofilms was tested in both Colección Española de Cultivos Tipo (CECT) 1002 and clinical C. albicans strains. Cytotoxicity was studied in human cell lines, and biofilm alterations were observed by scanning electron microscopy (SEM). Antifungal activity of the carbosilane dendritic molecules was assessed by monitoring cell viability using both established and novel cell viability assays. One out of 14 dendritic molecules tested, named BDSQ024, showed the highest activity with a minimum biofilm inhibitory concentration (MBIC) for biofilm formation and a minimum biofilm damaging concentration (MBDC) for existing biofilm of 16–32 and 16 mg/L, respectively. Synergy with amphotericin (AmB) and caspofungin (CSF) at non-cytotoxic concentrations was found. Therefore, dendritic compounds are exciting new antifungals effective at preventing Candida biofilm formation and represent a potential novel therapeutic agent for treatment of C. albicans infection in combination with existing clinical antifungals.

Sign in / Sign up

Export Citation Format

Share Document